학술논문
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
Document Type
Article
Author
Source
In Annals of Oncology September 2008 19(9):1547-1552
Subject
Language
ISSN
0923-7534